TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00625547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline
Description: Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa
Description: Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
Study: NCT00831129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: 4 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Rosiglitazone
Description: 1 tab daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 mg daily
Study: NCT03572387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: subcutaneously on days 1-5 at a dose of 40 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Azacitidine
Description: subcutaneously on days 1-5 at a dose of 40 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid
Description: 45 mg/m\^2, will be taken orally on days 3-7 of each cycle, divided into two doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: all trans retinoic acid
Description: 45 mg/m\^2, will be taken orally on days 3-7 of each cycle, divided into two doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupron
Description: 7.5 mg x 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron
Description: 7.5 mg x 1
Study: NCT04421846

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Description: Collection of biological samples and clinical/paraclinical data

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Description: Collection of biological samples and clinical/paraclinical data

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Description: Collection of biological samples and clinical/paraclinical data
Study: NCT02850510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Incredible Years parent training
Description: The IY parent training programme (3-8 years) developed by Webster-Stratton at the Parenting Clinic, University of Washington, is a manualised and video-based training programme for parents of young children with conduct problems (Webster-Stratton and Reid, 2003a). Parents assigned to the short IY Basic (S-IY) condition were divided into groups of 10-12 parents. The S-IY was led by two experienced group leaders and parents met weekly for two-hour sessions at a public health care center in the community. The group leaders led discussions regarding central aspects of parenting on the basis of the video vignettes, role play and homework.
Study: NCT01231009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular exercises
Description: Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vestibular exercises
Description: Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
Study: NCT01992601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.
Study: NCT03599570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP-HPV performance feedback intervention
Description: This intervention will be the addition of performance feedback (in the presence of communication skills).
Study: NCT02678117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin & Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate & Placebo
Study: NCT03401008

Intervention type: OTHER
Intervention: Oral manifestations
Description: To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.
Study: NCT02678117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin & Magnesium sulphate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00374634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH drug dose
Description: Individual rFSH dose (50, 75 or 100 IU rFSH/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard rFSH dose
Description: Standard rFSH dose was 75 IU/day
Study: NCT00927199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Oleic Canola Oil
Description: Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Oleic Canola/Flaxseed Oil Blend
Description: Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
Study: NCT01010659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrimal Tube
Description: Lacrimal Tube
Study: NCT03280589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sheetali/Sheekari Pranayama
Description: Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex \[6\]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sheetali/Sheekari Pranayama
Description: Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex \[6\]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sitting Quietly
Description: Participant breaths in their natural way with out instruction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing
Description: Participant is required to pay attention to each breath

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing
Description: Participant is required to pay attention to each breath
Study: NCT00927199

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western Dietary Control
Description: Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
Study: NCT03280589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing
Description: Participant is required to pay attention to each breath

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing
Description: Participant is required to pay attention to each breath
Study: NCT01119872

Intervention type: OTHER
Group type: OTHER
Intervention: Positive End-expiratory Pressure (PEEP)
Description: All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.~Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Positive End-expiratory Pressure (PEEP)
Description: All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.~Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment.
Study: NCT01823939

Intervention type: DRUG
Group type: OTHER
Intervention: iOWH032
Description: Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032.
Study: NCT02351934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
Study: NCT02423148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluoSCOPE
Study: NCT02483026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi vitamin
Description: Multi vitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: vitamin D
Description: Vitamin D
Study: NCT02293213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMR Referral
Description: EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMR Referral
Description: EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTIS Counseling
Description: Counseling from MotherToBaby teratogen information specialist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CTIS Counseling
Description: Counseling from MotherToBaby teratogen information specialist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Questionnaire
Description: Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Questionnaire
Description: Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraception Provision Appointment
Description: Appointment with contraception provider to discuss contraception options.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 Month Follow Up Questionnaire
Description: Questionnaire 3 months after CTIS counseling to assess contraception use and plans

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 3 Month Follow Up Questionnaire
Description: Questionnaire 3 months after CTIS counseling to assess contraception use and plans

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 Month Follow Up Questionnaire
Description: Questionnaire 6 months after CTIS counseling to assess contraception use and plans

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6 Month Follow Up Questionnaire
Description: Questionnaire 6 months after CTIS counseling to assess contraception use and plans
Study: NCT06110390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Description: An interface applied to the nostrils allowing fresh gas flows of up to 60 liters per minute and inspired oxygen concentrations of up to an fiO2 of 1.0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Description: An interface applied to the nostrils allowing fresh gas flows of up to 60 liters per minute and inspired oxygen concentrations of up to an fiO2 of 1.0

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal oxygen
Description: An interface applied to the nostrils allowing fresh gas flows of up to 60 liters per minute and inspired oxygen concentrations of up to an fiO2 of 1.0
Study: NCT02028078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin human
Description: Induces hypoglycaemia
Study: NCT04535310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision1® Daily Disposable Contact Lens
Description: Soft, spherical contact lens used to correct distance vision.
Study: NCT02544451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).
Study: NCT02976571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Sub cutaneous and/or Intraperitoneal Marcaine application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Sub cutaneous and/or Intraperitoneal Marcaine application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Sub cutaneous and/or Intraperitoneal Marcaine application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Sub cutaneous and/or Intraperitoneal Marcaine application
Study: NCT00860847

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aged garlic extract and Coenzyme Q10
Description: AGE (1200 mg) and CoQ10 (120 mg)
Study: NCT00532493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin
Description: Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill
Study: NCT04445727

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Will apply 1000mg of vitamin C, TENS and manual therapy. One session will be held per week for 6 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Will apply 1000mg of vitamin C, TENS and manual therapy. One session will be held per week for 6 weeks.
Study: NCT02397746

Intervention type: DEVICE
Intervention: total hip arthroplasty implant
Study: NCT03556033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 8 weeks treatment with dapagliflozin on top of insulin treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 8 weeks treatment with placebo capsules on top of insulin treatment
Study: NCT00512525

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ghrelin and saline (as placebo)
Description: Intravenous infusion
Study: NCT01699750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses, Phase 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lenses
Description: Silicone hydrogel contact lenses, Phase 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPTI-FREE® PUREMOIST® MPDS
Description: Contact lens care system, Phase 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE® PUREMOIST® MPDS
Description: Contact lens care system, Phase 2
Study: NCT04445727

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: spinal manipulation
Description: Applied spinal manipulations, tens and manual therapy.One session will be held per week for 6 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: spinal manipulation
Description: Applied spinal manipulations, tens and manual therapy.One session will be held per week for 6 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Received a manual therapy intervention and Tens. one session will be held per week for 6 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Received a manual therapy intervention and Tens. one session will be held per week for 6 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Received a manual therapy intervention and Tens. one session will be held per week for 6 weeks.
Study: NCT02157701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyherbal capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Study: NCT02009098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping